ebola
viru
ebov
infect
caus
frequent
fatal
hemorrhag
fever
hf
refractori
treatment
current
avail
antivir
therapeut
rna
interfer
repres
power
natur
occur
biolog
strategi
inhibit
gene
express
demonstr
util
inhibit
viral
replic
describ
develop
potenti
therapi
ebov
infect
base
small
interf
rna
sirna
method
four
sirna
target
polymeras
l
gene
zair
speci
ebov
zebov
either
complex
polyethylenimin
pei
formul
stabl
nucleic
acidlipid
particl
snalp
guinea
pig
treat
sirna
either
lethal
zebov
challeng
result
treatment
guinea
pig
pool
l
genespecif
sirna
deliv
pei
polyplex
reduc
plasma
viremia
level
partial
protect
anim
death
administ
shortli
zebov
challeng
evalu
pool
sirna
deliv
use
snalp
prove
system
efficaci
complet
protect
guinea
pig
viremia
death
administ
shortli
zebov
challeng
addit
experi
show
sirna
alon
could
complet
protect
guinea
pig
lethal
zebov
challeng
conclus
develop
technolog
potenti
yield
effect
treatment
ebov
hf
well
diseas
caus
agent
consid
biolog
threat
ebola
viru
ebov
famili
filovirida
singlestrand
negativesens
rna
viru
among
best
known
virus
caus
hemorrhag
fever
hf
although
outbreak
sporad
geo
graphic
restrict
area
central
africa
hf
caus
virus
remark
sever
associ
high
case
fatal
rate
often
exceed
addit
caus
human
infect
virus
decim
popul
wild
ape
central
africa
although
signific
advanc
made
develop
vaccin
combat
ebov
infect
present
vaccin
effect
therapi
avail
human
use
clearli
need
develop
effect
treatment
use
respond
outbreak
ebov
africa
counter
act
bioterror
may
occur
addit
unfortun
death
russian
scientist
accident
exposur
ebov
underscor
need
medic
countermeasur
postexposur
prophylaxi
ebov
particl
contain
noninfecti
rna
genom
encod
structur
protein
nonstructur
protein
gene
order
leader
nucleoprotein
np
virion
protein
vp
gli
coprotein
polymeras
l
protein
trailer
four
protein
associ
viral
genom
rna
ribonucleoprotein
complex
np
l
protein
l
protein
togeth
compris
polymeras
complex
respons
transcrib
replic
ebov
genom
l
protein
provid
rnadepend
rna
polymeras
activ
complex
thu
ideal
target
antivir
approachesnot
suppress
lead
nearli
total
loss
rna
synthesi
also
absenc
similar
protein
mammalian
cell
rna
interfer
rnai
repres
power
natur
occur
biolog
strategi
inhibit
gene
express
rnai
use
cellcultur
system
inhibit
replic
number
virus
caus
diseas
human
includ
hiv
hepat
b
viru
hbv
hepat
c
viru
influenza
viru
herpesvirus
polioviru
human
papillomaviru
respiratori
syncyti
viru
coxsackieviru
review
recent
use
inhibit
emerg
reemerg
virus
includ
marburg
viru
lymphocyt
choriomening
viru
sever
acut
respiratori
syndrom
coronaviru
although
vitro
result
highli
encourag
difficulti
involv
effect
deliveri
small
interf
rna
sirna
vivo
major
obstacl
use
therapeut
agent
sever
approach
employ
attempt
develop
vivo
sirna
deliveri
system
earli
proofofconcept
studi
includ
use
mous
model
rapid
hydrodynam
intraven
iv
inject
larg
volum
sirna
solut
howev
invas
procedur
appear
littl
util
human
use
sever
key
breakthrough
highlight
feasibl
use
sirna
antivir
therapeut
research
shown
cation
polym
abil
promot
success
deliveri
sirna
iv
administr
influenza
virusinfect
mice
recent
efficaci
lipidencapsul
sirna
target
hbv
demonstr
vivo
mous
model
hbv
replic
studi
sirna
target
hbv
rna
incorpor
special
liposom
form
stabl
nucleic
acidlipid
particl
snalp
administ
hbvinfect
mice
importantli
reduct
quantiti
hbv
dna
observ
specif
last
day
administr
use
snalp
postexposur
treatment
lethal
anim
model
ebov
hf
anim
model
ebov
infect
pathogenesi
develop
inbr
strain
guinea
pig
us
armi
medic
research
institut
infecti
diseas
serial
passag
zair
speci
ebov
zebov
mayinga
isol
time
result
guinea
pigadapt
strain
give
rise
high
plasma
viremia
typic
pfu
ml
highli
lethal
guinea
pig
typic
caus
death
day
challeng
infect
experi
perform
biosafeti
level
bsl
biocontain
research
conduct
complianc
anim
welfar
act
feder
statu
regul
relat
anim
experi
involv
anim
adher
principl
state
guid
care
use
laboratori
anim
facil
use
fulli
accredit
associ
assess
accredit
laboratori
anim
care
intern
noninfecti
mous
guinea
pig
clearanc
biodistribut
experi
conduct
protiva
biotherapeut
accord
guidelin
canadian
council
anim
care
sirna
sirna
design
target
individu
region
zebov
l
gene
accord
tuschl
rule
avail
http
wwwrockefelleredulabheadstuschlsirna
html
sirna
duplex
chemic
synthes
dharmacon
trilink
biotechnolog
sequenc
use
design
follow
sens
antisens
sens
antisens
sens
antisens
sens
antisens
sens
lipid
encapsul
sirna
sirna
encapsul
process
spontan
vesicl
format
report
jeff
et
al
snalp
compos
synthet
cholesterol
sigma
phospholipid
dspc
avanti
polar
lipid
peg
lipid
pegcdma
qmethoxi
poli
ethylen
glycol
carbamoyl
cation
lipid
dlindma
ndimethylaminopropan
molar
ratio
pegcdma
dlindma
synthes
describ
elsewher
result
snalp
dialyz
pb
filter
steril
filter
use
particl
size
rang
nm
typic
sirna
found
encapsul
within
liposom
cellcultur
experi
sirna
pmol
transfect
vero
cell
use
oligofectamin
invitrogen
accord
manufactur
instruct
h
transfect
vero
cell
infect
zebov
moi
cultur
fluid
collect
h
determin
level
infecti
zebov
vero
cell
collect
immunofluoresc
stain
vivo
pharmacokinet
tissu
distribut
radiolabel
snalp
prepar
plasma
clearanc
biodistribut
experi
incorpor
mci
nonexchang
lipid
label
h
cholesteryl
oleyl
ether
che
per
milligram
total
lipid
snalp
administ
singl
bolu
mg
sirna
per
kilogram
bodi
weight
femal
male
hartley
guinea
pig
charl
river
laboratori
via
ear
vein
inject
blood
collect
via
contralater
ear
nick
cours
h
h
guinea
pig
kill
co
inhal
harvest
tissu
homogen
lyse
matrix
tube
mp
biomed
contain
ml
distil
water
homogen
assay
radioact
liquid
scintil
count
picofluor
tissu
picofluor
blood
perkinelm
sirna
treatment
zebov
challeng
guinea
pig
sirna
nmol
total
mix
polyethylenimin
pei
vivo
jetpei
qbiogen
np
ratio
room
temperatur
min
accord
manufactur
instruct
guinea
pig
treat
via
intraperiton
ip
inject
ml
pei
polyplex
correspond
mgkg
sirna
three
hour
treatment
guinea
pig
challeng
via
subcutan
sc
inject
pfu
guinea
pigadapt
zebov
guinea
pig
receiv
addit
treatment
pei
polyplex
prepar
describ
immedi
administr
h
zebov
challeng
experi
evalu
snalp
deliveri
system
snalpformul
sirna
administ
ip
h
challeng
guinea
pig
via
sc
inject
pfu
guinea
pigadapt
zebov
guinea
pig
receiv
addit
treatment
snalpformul
sirna
viru
titrat
plaqu
assay
viru
titrat
perform
convent
plaqu
assay
vero
cell
cellcultur
fluid
blood
collect
guinea
pig
describ
elsewher
immunofluoresc
assay
cell
fix
neutralbuff
formalin
h
inactiv
infecti
zebov
fixat
cell
wash
copiou
amount
pb
process
immunofluoresc
stain
viral
protein
briefli
cell
incub
readytous
proteinas
k
dako
min
room
temperatur
cell
wash
pb
block
normal
goat
serum
kpl
laboratori
min
room
temperatur
viral
antigen
detect
incub
cell
mous
monoclon
antibodi
guinea
pigadapt
zebov
min
room
temperatur
rins
pb
incub
antimousealexafluor
conjug
invitrogen
min
room
temperatur
cell
counterstain
evan
blue
aid
visual
percentag
antigenposit
cell
determin
examin
random
field
fluoresc
vivo
cytokin
induct
snalp
administ
ml
pb
icr
mice
harlan
standard
iv
inject
later
tail
vein
blood
collect
cardiac
punctur
h
administr
process
plasma
cytokin
analysi
level
mous
cytokin
interferon
ifn
ifnb
measur
use
sandwich
elisa
kit
pbl
biomed
accord
manufactur
instruct
one
hour
challeng
daili
day
thereaft
guinea
pig
treat
via
snalp
deliveri
system
sirna
pool
mgkg
equival
dose
irrelev
scrambl
sequenc
scr
plasma
viremia
level
determin
day
viremia
data
mean
sd
n
p
shown
plasma
viremia
level
surviv
rate
b
inbr
strain
guinea
pig
zebov
challeng
one
hour
challeng
daili
day
thereaft
guinea
pig
treat
via
snalp
deliveri
system
pool
sirna
mgkg
equival
dose
irrelev
scrambl
sequenc
scr
sirna
alon
plasma
viremia
level
determin
day
viremia
data
p
valu
commean
sd
n
p
parison
scr
determin
whether
sirna
inhibit
replic
zebov
vitro
first
transfect
vero
cell
either
pool
differ
sirna
specif
zebov
l
gene
equival
dose
irrelev
scrambl
sequenc
use
vero
cell
lack
structur
gene
ifna
ifnb
thu
preclud
confound
effect
cytokin
variou
time
point
transfect
h
transfect
cell
infect
zebov
cell
cultur
fluid
harvest
h
later
determin
level
viru
product
result
show
sirna
pool
inhibit
product
infecti
zebov
depend
transfect
cell
infect
figur
immunofluoresc
antibodi
stain
abl
demonstr
mean
sd
reduct
student
test
p
p
number
cell
express
ebov
protein
figur
individu
test
l
genespecif
sirna
yield
similar
result
data
shown
irrelev
scrambl
sequenc
inhibit
product
infecti
zebov
fail
reduc
number
cell
express
ebov
protein
figur
test
whether
pool
sirna
could
protect
guinea
pig
lethal
zebov
challeng
although
mous
guinea
pig
model
avail
zebov
infect
chose
use
guinea
pig
experi
appear
basi
evalu
coagul
chang
reproduc
human
filovir
infect
slightli
better
mice
mous
model
avail
filovirus
wherea
guinea
pig
use
studi
sudan
speci
ebov
model
infect
sever
strain
ebovrel
marburg
viru
first
vivo
experi
guinea
pig
treat
either
l
genespecif
sirna
pool
n
p
irrelev
scrambl
sequenc
mix
n
p
pei
inject
retroorbit
h
zebov
challeng
guinea
pig
receiv
equival
dose
sirna
mgkg
h
zebov
challeng
signific
reduct
plasma
viremia
p
p
demonstr
day
challeng
guinea
pig
receiv
l
genespecif
sirna
pool
compar
guinea
pig
receiv
irrelev
scrambl
sequenc
figur
control
guinea
pig
treat
irrelev
scrambl
sequenc
die
euthan
day
challeng
wherea
guinea
pig
treat
sirna
pool
surviv
guinea
pig
either
die
euthan
day
respect
improv
potenc
l
genespecif
sirna
encapsul
lipid
particl
previous
shown
antivir
efficaci
mous
model
hbv
infect
snalp
method
yield
particl
uniform
reproduc
perform
specif
regardless
sirna
payload
particl
size
snalp
prepar
use
mean
sd
present
studi
nm
mean
sd
polydispers
encapsul
mean
sd
effici
nucleic
acid
mean
sd
lipid
ratio
mg
sirnammol
lipid
assess
plasma
clearanc
biodistribut
snalp
prepar
contain
nonexchang
lipid
label
hche
describ
elsewher
plasma
clearanc
snalp
guinea
pig
determin
singl
iv
administr
previous
shown
iv
administr
unstabil
unformul
sirna
mice
result
rapid
elimin
plasma
compart
elimin
halflif
min
calcul
serum
halflif
snalp
use
present
studi
min
administr
guinea
pig
figur
liver
known
one
earli
primari
site
zebov
replic
rodent
nonhuman
primat
also
interest
determin
pattern
biodistribut
snalp
administr
shown
figur
substanti
quantiti
snalp
accumul
liver
within
h
inmean
sd
jection
substanti
fewer
snalp
accumul
spleen
lung
mean
sd
mean
sd
brain
mean
sd
gonad
tissu
mean
sd
ovari
test
respect
thymu
mean
sd
remain
rel
cessibl
accumul
snalp
rapid
select
accumul
snalp
liver
compar
favor
result
target
deliveri
technolog
use
receptorligand
interact
well
result
target
technolog
evalu
pool
l
genespecif
sirna
use
snalp
deliveri
system
rodent
model
ebov
hf
previou
challeng
experi
guinea
pig
receiv
sirna
pool
mgkg
control
guinea
pig
receiv
irrelev
scrambl
sequenc
mgkg
howev
experi
guinea
pig
treat
sirna
zebov
challeng
rather
treatment
initi
h
challeng
addit
treatment
administ
daili
day
infect
plasma
viremia
level
peak
day
guinea
pig
model
detect
day
guinea
pig
treat
sirna
pool
rang
log
pfuml
control
guinea
pig
figur
one
guinea
pig
treat
sirna
pool
die
day
like
toxic
given
unabl
demonstr
presenc
infecti
zebov
anim
anoth
guinea
pig
treatment
group
euthan
day
death
could
attribut
viral
replic
either
remain
guinea
pig
treat
sirna
pool
show
evid
ill
surviv
zebov
challeng
wherea
control
guinea
pig
die
euthan
day
figur
experi
perform
assess
efficaci
sirna
pool
lower
dose
individu
evalu
l
genespecif
sirna
zebovinfect
guinea
pig
receiv
lower
dose
mgkg
sirna
pool
complet
protect
viremia
death
figur
although
vari
level
viremia
mortal
observ
among
group
treat
individu
sirna
figur
lowest
level
mortal
associ
guinea
pig
recent
studi
demonstr
synthet
sirna
induc
high
level
type
ifn
inflammatori
cytokin
mammalian
cell
immun
respons
could
contribut
antivir
efficaci
toxic
associ
system
administr
formul
sirna
immunostimulatori
properti
sirnacontain
snalp
examin
directli
iv
administr
mice
strikingli
snalpformul
sirna
includ
irrelev
scrambl
sequenc
induc
ifna
ifnb
serum
inject
mice
figur
guinea
pig
mice
treat
immunostimulatori
snalp
show
symptom
system
toxic
includ
transient
decreas
bodi
weight
piloerect
data
shown
previous
shown
associ
sirnamedi
stimul
mammalian
innat
immun
system
advers
effect
evid
control
anim
treat
pb
anim
inject
empti
liposom
nake
sirna
note
confer
greatest
benefit
use
treat
zebovinfect
anim
least
immunostimulatori
sirna
examin
provid
evid
support
rnaispecif
antivir
effect
infect
experi
current
known
effect
preor
postexposur
therapi
human
ebov
infect
time
treat
patient
infect
ebov
consist
palli
care
direct
toward
maintain
blood
volum
electrolyt
balanc
number
therapiesinclud
ifna
heparin
convalesc
serum
equin
antiebov
immunoglobulinhav
use
treat
infect
human
andor
nonhuman
primat
result
inconsist
gener
littl
effect
although
number
postexposur
treatment
shown
promis
rodent
model
ebov
hf
none
shown
success
nonhuman
primat
date
postexposur
treatment
shown
protect
nonhuman
primat
challeng
zebov
strategi
design
modul
manifest
diseas
rather
block
replic
viru
studi
rhesu
monkey
demonstr
postexposur
strategi
mitig
coagul
disord
typifi
ebov
infect
improv
surviv
howev
improv
efficaci
clearli
need
although
assur
snalpbas
sirna
strategi
describ
protect
ebov
infect
morerigor
nonhuman
primat
model
reason
optim
light
compar
data
histor
studi
specif
note
sever
previou
studi
shown
complet
postexposur
protect
mice
guinea
pig
lethal
zebov
challeng
howev
case
rodent
protect
viremia
subsequ
transit
strategi
nonhuman
primat
uniformli
unsuccess
protect
macaqu
lethal
infect
suggest
inabl
complet
inhibit
viremia
rodent
predict
unfavor
outcom
nonhuman
primat
present
studi
administr
sirna
unabl
detect
viremia
zebovchalleng
guinea
pig
clearli
observ
guarante
success
snalpbas
sirna
approach
nonhuman
primat
hand
offer
hope
prospect
success
least
improv
focus
l
gene
zebov
demonstr
vivo
util
snalp
technolog
futur
studi
focu
evalu
sequenc
ebov
gene
possibl
employ
cocktail
sirna
increas
antivir
effect
furthermor
uniqu
mechan
rnai
may
benefit
combin
sirna
treatment
ebov
infect
complementari
antivir
approach
immunoglobulin
coagul
inhibitor
